Skip to main content

Table 2 Comparison between various metrics in planning phase I. The data are the median and range values of the five patients included into the study. PTV70+PET corresponds to the PTV70 encompassing the PTVPET, while PTV70 is the part of the PTV70 outside of the PTVPET. In a similar way, PTV56 is the part of the PTV56 outside of the PTV70

From: Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc

PHASE I

RapidArc

Helical Tomotherapy

p-value

Median

Min - Max

Median

Min - Max

QVH indexes

VQ=0.95 (%)

99.9

98.7–100.0

97.2

92.7–97.6

0.043

VQ=1.05 (%)

0.0

0.0–0.2

3.7

2.0–4.9

0.043

QF (%)

1.4

1.2–1.8

1.9

1.8–2.3

0.043

PTV70+PET

D98% (Gy)

67.3

67.0–67.8

67.4

66.7–67.8

n.s.

D95% (Gy)

68.0

67.7–68.4

68.3

67.5–68.5

n.s.

D50% (Gy)

70.1

70.0–70.4

70.1

69.8–70.3

n.s.

D2% (Gy)

79.1

74.9–81.3

79.4

76.3–82.2

n.s.

V95% (%)

99.4

99.1–99.8

99.4

98.3–99.8

n.s.

HI

0.2

0.1–0.2

0.2

0.1–0.2

n.s.

PTV70

D98% (Gy)

67.2

66.9–67.8

67.2

66.6–67.7

n.s

D95% (Gy)

67.9

67.5–68.3

68.1

67.4–68.4

n.s

D50% (Gy)

69.9

69.8–70.4

70.0

69.7–70.3

n.s

D2% (Gy)

72.1

72.0–72.5

71.5

70.8–72.0

0.043

V95% (%)

99.3

98.9–99.8

99.3

98.1–99.8

n.s

V107% (%)

0.0

0.0–0.0

0.0

0.0–0.1

n.s

HI

0.1

0.1–0.1

0.1

0.0–0.1

n.s

PTV56

D98% (Gy)

54.1

53.9–54.6

54.6

53.9–54.9

n.s.

D95% (Gy)

54.6

54.4–54.9

55.0

54.3–55.2

n.s.

D50% (Gy)

56.6

56.4–57.0

55.9

55.8–56.2

0.043

D2% (Gy)

68.2

67.4–68.5

68.0

65.9–68.2

0.043

V95% (%)

99.6

99.2–99.9

99.8

99.5–99.9

n.s.

V107% (%)

13.8

11.7–21.7

11.5

9.8–20.3

n.s.

HI

0.2

0.2–0.3

0.2

0.2–0.3

n.s.

PRV SC

D2% (Gy)

47.6

47.1–47.8

47.2

43.0–47.6

-a

PRV BS

D2% (Gy)

39.2

34.0–47.2

35.8

25.4–43.4

-a

Ipsilateral parotid

Dmean (Gy)

28.8

28.5–29.5

28.7

27.1–29.8

-a

Contralateral parotid

Dmean (Gy)

24.8

23.9–25.1

22.9

21.3–25.2

-a

Conformity Index

CI PTV70

1.2

1.2–1.2

1.2

1.1–1.2

n.s.

CI PTV56

1.7

1.6–2.0

1.5

1.4–1.8

0.043

  1. ano Wilcoxon signed-rank test performed as the dose to OAR had to reach the constraint but was not further optimized in planning phase I